Searched for
DRUGS MAKER
US DOJ closes criminal probe into Abbott over baby formula plant: ReportThe US Justice Department has reportedly ended its criminal investigation into Abbott Laboratories concerning its baby formula plant, which...- The hidden reason global capital is looking beyond India for future growthForeign investors are reallocating capital away from India towards markets like Taiwan and South Korea that offer stronger exposure to AI a...
- India’s GLP-1 boom loses steam as price war, weak retention hit generic weight-loss drug salesInitial excitement for India's generic weight-loss drugs is fading. Domestic manufacturers are lowering sales targets due to slower-than-ex...
- Brokerages stay bullish on Laurus Labs as CDMO momentum and margins improveLaurus Labs' stock has surged 30% on robust FY26 results, fueled by a booming contract manufacturing business and improved product mix. The...
- Google poised to lose two more senior AI staffers to AnthropicTheir moves rattled investors and cast new doubt on Google’s ability to compete in the fierce race to build better models.Shares of Alphabe...
- ITC bulking up with products rich in protein and fibre: Sanjiv Puri“India is also a protein-deficient market. We already have offerings such as high-protein atta, soya chunks and protein shakes, and we will...
- Shopify to ban vapes as US authorities crack down on illegal e-cigarettes industryShopify is poised to ban all vape sales from its platform this week, responding to pressure from U.S. state attorneys general. This move ta...
- Coke, Pepsi, Red Bull to add QR codes linking to ingredient information in USMajor beverage companies are now placing QR codes on their products across the US, offering consumers direct access to detailed ingredient ...
- Drugmakers yet to see gains from government's minimum import price policyGovernment's Minimum Import Price (MIP) initiative to boost domestic drug makers faces a slow start. Despite setting price thresholds for k...
- Stocks in news: Sun Pharma, Tech Mahindra, Tata Motors, Voltas, ONGCIndian markets saw a dip on Friday, with IT stocks leading the decline. Analysts suggest profit-taking occurred near the 24,150 mark. Despi...
- India raises price cap on cancer drugs to tackle shortageIndia's drug price regulator has increased the ceiling prices of cancer drugs cisplatin and carboplatin by 50% to tackle shortages caused b...
- Cancer drug prices raised 50% as NPPA acts on shortage concernsIndia's drug pricing authority has approved a 50% price hike for essential anti-cancer drugs carboplatin and cisplatin. This decision follo...
- US stocks: US market rises as tech shares gain, Middle East tensions easeWall Street indexes opened higher on Tuesday, driven by a second consecutive day of gains for chipmakers. Easing Middle East tensions also ...
- Regulator, cos discuss price hike for some cancer drugsIndia's drug pricing authority may soon approve a price hike for vital platinum-based cancer medicines. These drugs, including carboplatin ...
- Drug companies directed to step up vigil on adverse reactionsIndia's drug regulator, CDSCO, has mandated all drug companies to establish systems for tracking adverse drug reactions. This move comes am...
- From diapers to drugs: How India's global corporate hubs are putting AI to workHeads of several Global Capability Centres (GCCs) told Reuters they are deploying AI across a host of functions - from marketing and conten...
- Bio Medica Laboratories shares to debut today. Here's what GMP suggests ahead of listingBio Medica Laboratories' shares are set to list on the NSE SME platform amidst weak grey market sentiment, with the IPO currently trading a...
- Stocks in news: RIL, Coal India, IDFC First Bank, Zydus Life, ONGCMarkets traded subdued with the India VIX correcting nearly 15% this week, though this hasn't significantly impacted benchmark index moveme...
- Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...
- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
Load More
